Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Ischemic Stroke
← New Search

Ischemic Stroke

Educational clinical summary of Ischemic Stroke for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This document provides comprehensive medical information for educational purposes and is intended for use by healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made based on individual patient circumstances, current clinical guidelines, and the judgment of a qualified healthcare provider. While every effort has been made to ensure accuracy, medical knowledge is constantly evolving.

Overview

  • Definition: Ischemic stroke, also known as brain ischemia or cerebral infarction, is an acute neurological deficit resulting from focal cerebral, spinal cord, or retinal infarction. It occurs due to an interruption of blood supply to a part of the brain, leading to cellular death.
  • Epidemiology:
    • Stroke is a leading cause of long-term disability and the fifth leading cause of death in the United States.
    • Approximately 87% of all strokes are ischemic.
    • Incidence increases with age, doubling each decade after age 55.
    • Affects men and women relatively equally, though women have a higher lifetime risk due to longer lifespan.
    • Racial disparities exist: incidence and mortality are significantly higher among Black and Hispanic individuals compared to White individuals.
    • Prevalence in the US is estimated to be over 7 million individuals with a history of stroke.
  • Classification: The Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification is widely used to categorize ischemic stroke based on etiology:
    1. Large-artery atherosclerosis (LAA): Stenosis or occlusion of a major intracranial or extracranial artery (e.g., carotid or vertebral artery) due to atherosclerosis.
    2. Cardioembolism (CE): Emboli originating from the heart (e.g., atrial fibrillation, valvular heart disease, patent foramen ovale with paradoxical embolism, left ventricular thrombus).
    3. Small-vessel occlusion (SVO) / Lacunar Stroke: Occlusion of a single penetrating artery supplying subcortical structures (e.g., basal ganglia, internal capsule, pons) due to lipohyalinosis or microatheroma.
    4. Stroke of other determined etiology: Less common causes, including dissection (carotid or vertebral), vasculitis, hypercoagulable states, genetic disorders (e.g., CADASIL), migraine, drug abuse.
    5. Stroke of undetermined etiology: Includes cases where two or more potential causes are identified, no cause is found despite comprehensive evaluation (cryptogenic stroke), or evaluation is incomplete.

Pathophysiology

  • Mechanism: Ischemic stroke results from a sudden reduction in cerebral blood flow below a critical threshold (typically <20 mL/100g/min). This leads to:
    • Ischemic Penumbra: An area of hypoperfused but still viable brain tissue surrounding the core infarct. This tissue is at risk of infarction if reperfusion is not achieved promptly. The goal of acute stroke therapy is to salvage the penumbra.
    • Ischemic Cascade: A series of biochemical events initiated by energy failure (due to lack of oxygen and glucose) leading to neuronal death:
      • Excitotoxicity: Release of excessive excitatory neurotransmitters (e.g., glutamate) leading to calcium influx and neuronal damage.
      • Oxidative Stress: Formation of reactive oxygen species (free radicals) that damage cellular components.
      • Inflammation: Activation of microglia, astrocytes, and infiltration of leukocytes, contributing to secondary injury.
      • Apoptosis: Programmed cell death pathways are activated.
    • Core Infarct: The central area of irreversible cell death due to severe ischemia (typically <10 mL/100g/min).
  • Risk Factors:
    • Modifiable:
      • Hypertension (most important): Increases risk 2-4 fold.
      • Diabetes Mellitus: Increases risk 1.5-3 fold.
      • Dyslipidemia: Elevated LDL cholesterol, low HDL cholesterol.
      • Atrial Fibrillation: Confers a 5-fold increased risk; accounts for 15-20% of ischemic strokes.
      • Smoking: Doubles risk; dose-dependent.
      • Obesity: BMI >30 kg/m².
      • Physical Inactivity: Lack of regular exercise.
      • Unhealthy Diet: High in saturated/trans fats, sodium, refined carbohydrates.
      • Obstructive Sleep Apnea (OSA).
      • Carotid Artery Stenosis: Especially symptomatic stenosis.
      • Other Cardiac Conditions: Heart failure, recent MI, valvular heart disease, patent foramen ovale (PFO).
      • Sickle Cell Disease.
      • Illicit Drug Use: Cocaine, amphetamines.
    • Non-modifiable:
      • Age: Risk increases with age.
      • Sex: Slightly higher incidence in men at younger ages, but women have higher lifetime risk.
      • Race/Ethnicity: Higher incidence and mortality in Black and Hispanic populations.
      • Family History/Genetics: Genetic predispositions, e.g., CADASIL, Fabry disease.
      • Prior Stroke or Transient Ischemic Attack (TIA): Strongest risk factor for recurrent stroke.
  • Protective Factors:
    • Effective management of modifiable risk factors (e.g., blood pressure control, diabetes management, lipid-lowering therapy).
    • Anticoagulation for atrial fibrillation.
    • Antiplatelet therapy for individuals with prior stroke/TIA or high cardiovascular risk.
    • Healthy lifestyle choices: regular physical activity (e.g., 150 minutes of moderate-intensity aerobic exercise per week), balanced diet (e.g., Mediterranean diet), smoking cessation, moderate alcohol consumption.

Clinical Presentation

Signs and Symptoms

Stroke symptoms are characterized by sudden onset. The mnemonic FAST is widely used: * Face drooping (unilateral) * Arm weakness (unilateral) * Speech difficulty (slurred speech, difficulty finding words, difficulty understanding speech) * Time to call emergency services

  • Cardinal Features:
    • Unilateral Weakness or Numbness: Hemiparesis or hemiplegia affecting face, arm, or leg, or combinations thereof.
    • Speech and Language Deficits: Aphasia (expressive, receptive, global), dysarthria (slurred speech).
    • Visual Disturbances: Monocular blindness (amaurosis fugax, often TIA), homonymous hemianopia, diplopia.
    • Ataxia/Balance Issues: Sudden loss of balance or coordination, dizziness.
    • Cognitive Deficits: Acute confusion, neglect (unilateral spatial neglect).
  • Early Signs: Sudden onset of focal neurological deficits, often progressing over minutes to hours. The exact symptoms depend on the occluded artery and brain region involved. Examples:
    • Middle Cerebral Artery (MCA) infarct: Contralateral hemiparesis (face and arm > leg), contralateral sensory loss, aphasia (dominant hemisphere), neglect (non-dominant hemisphere), gaze preference.
    • Anterior Cerebral Artery (ACA) infarct: Contralateral leg weakness and sensory loss (leg > arm), abulia, primitive reflexes.
    • Posterior Cerebral Artery (PCA) infarct: Contralateral homonymous hemianopia, memory deficits, sensory loss.
    • Vertebrobasilar artery infarct: Ataxia, vertigo, diplopia, dysarthria, dysphagia, cranial nerve palsies, bilateral weakness.
    • Lacunar infarcts: Pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand syndrome.
  • Advanced Signs: Worsening of initial deficits, developing cerebral edema leading to signs of increased intracranial pressure (headache, vomiting, decreased level of consciousness), brainstem compression, or herniation.
  • Atypical Presentations:
    • Isolated headache (more common in hemorrhagic stroke, but can occur in ischemic stroke, especially with carotid dissection or cerebral venous thrombosis).
    • Isolated dizziness/vertigo (if not accompanied by other brainstem signs).
    • Seizures (especially with cortical involvement).
    • Transient global amnesia (though typically not stroke).
    • Symptoms fluctuating over minutes to hours (crescendo TIA).

Physical Examination

The physical examination in acute stroke focuses on rapid neurological assessment to localize the lesion and quantify stroke severity, often using the National Institutes of Health Stroke Scale (NIHSS). - Inspection: * Facial Droop: Asymmetry, drooping of one side of the mouth. * Speech: Slurred (dysarthria), incoherent (aphasia), or absent. * Gaze Preference: Deviation of eyes to one side (often towards the side of the lesion in cortical strokes). * Pronator Drift: Inability to maintain an arm outstretched with palms up without the hand pronating and drifting downwards. * Movement: Spontaneous movements, presence of weakness (hemiparesis/hemiplegia). * Neglect: Inattention to one side of the body or space. - Palpation: * Carotid Bruits: Presence of bruits may indicate carotid stenosis but is not diagnostic and should not delay imaging. * Cardiac Palpation: Irregular pulse suggests atrial fibrillation. - Special Tests: * National Institutes of Health Stroke Scale (NIHSS): A standardized, 15-item neurological examination score (0-42) used to assess stroke severity. Higher scores indicate greater severity. Components include: * Level of Consciousness (LOC) * LOC Questions (Month, Age) * LOC Commands (Open/Close Eyes, Grip/Release Hand) * Best Gaze (horizontal eye movements) * Visual Fields * Facial Palsy * Motor Arm (left, right) * Motor Leg (left, right) * Limb Ataxia (finger-nose, heel-shin) * Sensory (pinprick perception) * Best Language (aphasia assessment) * Dysarthria (speech clarity) * Extinction and Inattention (neglect) * Blood Pressure Measurement: Crucial for acute management. * Cardiac Auscultation: Murmurs, irregular rhythm. * Fundoscopy: Rarely performed acutely but can show signs of vascular disease or papilledema (if increased ICP, usually not acute stroke).

Diagnostic Approach

History Taking

  • Key Questions:
    • Time of Symptom Onset: Crucial for determining eligibility for reperfusion therapies ("Last Known Normal" - LKN). If awakened with symptoms, LKN is considered the time the patient was last known to be symptom-free.
    • Nature of Symptoms: Detailed description of initial symptoms and their evolution.
    • Associated Symptoms: Headache, nausea/vomiting, dizziness, seizures.
    • Risk Factors: History of hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, previous stroke/TIA, family history.
    • Medications: Anticoagulants, antiplatelets, insulin, oral hypoglycemics.
    • Recent Trauma or Procedures: Especially neck trauma (dissection).
    • Allergies.
    • Current Medical Conditions.
  • Red Flags:
    • Sudden onset of focal neurological deficits: This is the cardinal red flag.
    • Rapidly progressing neurological deficits: Suggests ongoing ischemia.
    • Altered level of consciousness: May indicate large territory infarct, brainstem involvement, or secondary complications like edema.
    • Severe headache with focal deficit: Raises suspicion for hemorrhagic stroke, subarachnoid hemorrhage, or dissection.
    • Neck stiffness/nuchal rigidity: Suggests meningeal irritation (e.g., SAH), though rare in ischemic stroke.

Laboratory Tests

Laboratory tests are primarily used to assess for contraindications to thrombolysis, identify underlying stroke etiologies, and monitor general health. - First-Line (obtain within minutes of arrival): * Complete Blood Count (CBC): Assess for anemia, thrombocytosis, leukocytosis (infection/inflammation). * Basic Metabolic Panel (BMP): Glucose (hypoglycemia can mimic stroke), electrolytes, renal function (creatinine for contrast safety). * Coagulation Studies: Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (aPTT) – essential before thrombolysis to rule out coagulopathy. * Cardiac Markers: Troponin T/I, CK-MB (rule out concomitant acute coronary syndrome; elevated troponin can indicate cardiac strain due to stroke or pre-existing cardiac disease). * Electrocardiogram (ECG): To detect atrial fibrillation, other arrhythmias, or signs of myocardial ischemia. * Point-of-care glucose: Essential to rule out hypoglycemia. - Confirmatory (for etiology workup, usually after acute stabilization): * Lipid Panel: For risk factor assessment and management. * HbA1c: For long-term glucose control. * Inflammatory Markers: ESR, CRP (if vasculitis suspected). * Thrombophilia Workup: For cryptogenic stroke, especially in younger patients (e.g., Protein C/S, Antithrombin III, Factor V Leiden, Prothrombin gene mutation, Antiphospholipid antibodies). * Urine Toxicology Screen: If illicit drug use is suspected. - Monitoring: * Repeat Glucose: To maintain euglycemia. * Electrolytes and Renal Function: Especially if IV fluids are used. * Serial CBC: To monitor for bleeding complications (if thrombolysis/anticoagulation).

Imaging

Rapid brain imaging is paramount to differentiate ischemic stroke from hemorrhagic stroke and to identify large vessel occlusions. - Recommended (within 20-25 minutes of arrival): * Non-contrast Computed Tomography (NCCT) of the Brain: * Primary purpose: To rapidly exclude intracranial hemorrhage, which is an absolute contraindication to IV thrombolysis. * Early ischemic changes: Subtle signs of ischemia (e.g., sulcal effacement, loss of grey-white differentiation, hyperdense MCA sign) may be visible within hours, but their absence does not rule out stroke. * CT Angiography (CTA) of the Head and Neck: * Purpose: To identify large vessel occlusion (LVO) in the intracranial or extracranial carotid and vertebral arteries. Essential if endovascular thrombectomy is being considered. * Provides information on collateral circulation. * CT Perfusion (CTP): * Purpose: To quantify areas of ischemic core (irreversibly damaged tissue) and penumbra (salvageable tissue). * Used to identify patients who may benefit from extended window thrombectomy (6-24 hours from LKN) by demonstrating a favorable mismatch between core and penumbra (e.g., DAWN, DEFUSE 3 criteria). - Advanced (often performed later for etiology or in specific situations): * Magnetic Resonance Imaging (MRI) of the Brain: * Diffusion-Weighted Imaging (DWI): Most sensitive sequence for detecting acute ischemic stroke (can detect ischemia within minutes of onset) and can differentiate acute from old infarcts. * Fluid-Attenuated Inversion Recovery (FLAIR): Helps estimate stroke age ("FLAIR-DWI mismatch" in wake-up strokes for thrombolysis eligibility within 4.5 hours of symptom onset). * Magnetic Resonance Angiography (MRA): Provides detailed images of cerebral vasculature without ionizing radiation or iodine contrast (can use gadolinium). * Echocardiography (Transthoracic [TTE] or Transesophageal [TEE]): * Purpose: To evaluate for cardiac sources of emboli (e.g., atrial fibrillation, valvular disease, PFO, mural thrombus). TEE is more sensitive for atrial appendage thrombi or PFO. * Conventional Angiography (Digital Subtraction Angiography - DSA): * Gold standard for detailed visualization of cerebral vasculature. Invasive, typically reserved for complex cases (e.g., vasculitis, dissection, pre-procedural planning for revascularization) or when non-invasive imaging is inconclusive.

Management

Acute Management

The immediate goal is to restore blood flow to the ischemic brain tissue as quickly as possible to salvage the penumbra. "Time is Brain" is the guiding principle.

  • Immediate (within minutes of arrival - often pre-hospital or ED arrival):
    • Activation of Stroke Team/Code Stroke: Rapid triage and notification.
    • ABCs (Airway, Breathing, Circulation): Assess and stabilize. Ensure adequate oxygenation (maintain SpO2 >94%).
    • Rapid Neurological Assessment: Perform initial NIHSS.
    • Determine Last Known Normal (LKN): Crucial for reperfusion therapy eligibility.
    • Emergent Non-contrast CT Brain: Within 20 minutes of ED arrival, ideally.
    • Obtain Labs: Point-of-care glucose, CBC, PT/INR/aPTT, cardiac enzymes, ECG.
    • Establish IV access.
  • Stabilization (concurrent with immediate steps):
    • Blood Pressure Management:
      • If eligible for IV thrombolysis: Maintain SBP <185 mmHg and DBP <110 mmHg before starting alteplase. During and for 24 hours after alteplase, maintain SBP <180 mmHg and DBP <105 mmHg. Labetalol, nicardipine, or clevidipine are preferred agents.
      • If NOT eligible for IV thrombolysis: Permissive hypertension is generally recommended to maintain cerebral perfusion, unless SBP >220 mmHg or DBP >120 mmHg, or if there are other compelling indications for lowering BP (e.g., acute MI, aortic dissection, acute renal failure, symptomatic heart failure). In these cases, lower BP by 15% in the first 24 hours.
    • Glucose Management: Maintain blood glucose in the range of 80-180 mg/dL (4.4-10 mmol/L). Treat hypoglycemia aggressively.
    • Temperature Control: Treat fever (>37.5°C) with antipyretics (e.g., acetaminophen) to minimize metabolic demand.
    • Dysphagia Screening: Perform a swallow screen before allowing oral intake of food, fluids, or medications to prevent aspiration pneumonia.
    • Head Position: Keep head of bed flat (0-15 degrees) initially to improve cerebral blood flow, unless contraindicated.
  • Emergency (Reperfusion Therapies):
    • Intravenous Thrombolysis (Alteplase, recombinant tissue plasminogen activator - rt-PA):
      • Mechanism: Dissolves the clot obstructing blood flow.
      • Dosage: 0.9 mg/kg IV (maximum 90 mg). Administer 10% of the total dose as an IV bolus over 1 minute, followed by the remaining 90% infused over 60 minutes.
      • Time Window: 0-4.5 hours from LKN for most patients. Extended window to 4.5 hours for select patients without additional risk factors for hemorrhage (e.g., no severe stroke NIHSS >25, no history of both stroke and diabetes).
      • Key Inclusion Criteria: Diagnosis of ischemic stroke causing measurable neurological deficit, LKN within 4.5 hours.
      • Key Exclusion Criteria (Absolute): Active internal bleeding, intracranial hemorrhage on CT, recent intracranial surgery/head trauma (<3 months), history of intracranial hemorrhage, uncontrolled hypertension (SBP >185 mmHg or DBP >110 mmHg despite treatment), acute bleeding diathesis (platelets <100,000, INR >1.7, aPTT > normal), glucose <50 mg/dL.
      • Key Exclusion Criteria (Relative): Minor or rapidly improving symptoms, major surgery/serious trauma within 14 days, GI/GU hemorrhage within 21 days, recent MI within 3 months, seizures at onset with postictal residual neurological impairments.
    • Endovascular Thrombectomy (Mechanical Thrombectomy):
      • Mechanism: Physically removes the clot from a large cerebral artery using a catheter-based device.
      • Primary Indication: Acute ischemic stroke due to large vessel occlusion (LVO) in the anterior circulation (intracranial internal carotid artery, M1 or M2 segments of MCA, vertebral/basilar for posterior circulation).
      • Time Window:
        • 0-6 hours from LKN: Recommended for patients with LVO who meet standard criteria (e.g., NIHSS ≥6, ASPECTS ≥6). Based on MR CLEAN, ESCAPE, REVASCAT, EXTEND-IA, SWIFT PRIME trials.
        • 6-24 hours from LKN: For select patients with LVO AND a favorable perfusion imaging profile (e.g., CT perfusion or MRI DWI/FLAIR) demonstrating salvageable brain tissue (penumbra). Based on DAWN and DEFUSE 3 trials.
          • DAWN criteria: LVO in anterior circulation, NIHSS ≥10 and infarct volume <20 mL, OR NIHSS ≥6 and infarct volume <30 mL (for age <80), OR NIHSS ≥6 and infarct volume <50 mL (for age ≥80).
          • DEFUSE 3 criteria: LVO in anterior circulation, NIHSS ≥6, infarct volume <70 mL, ratio of hypoperfusion to core >1.8.
    • Antiplatelet Therapy (Aspirin):
      • Administer aspirin 325 mg orally or rectally within 24-48 hours of stroke onset for most patients not receiving thrombolysis.
      • If IV alteplase is administered, delay antiplatelet agents for at least 24 hours after alteplase administration and after a follow-up CT scan confirms no hemorrhage.

Chronic Management (Secondary Prevention & Rehabilitation)

Long-term management focuses on preventing recurrent stroke and maximizing functional recovery.

  • Pharmacological:
    • Antiplatelet Agents:
      • Non-cardioembolic stroke/TIA:
        • Aspirin (ASA): 50-325 mg daily (e.g., 81 mg or 325 mg).
        • Clopidogrel: 75 mg daily (if aspirin intolerant or as alternative).
        • Aspirin + Dipyridamole (extended release): 25 mg/200 mg BID (alternative to aspirin or clopidogrel).
        • Dual Antiplatelet Therapy (DAPT): Aspirin + Clopidogrel for 21-90 days for minor ischemic stroke (NIHSS ≤5) or high-risk TIA (ABCD² score ≥4), if initiated within 24 hours of symptom onset. (Based on POINT and CHANCE trials).
      • Cardioembolic stroke (e.g., Atrial Fibrillation):
        • Oral Anticoagulation: Preferred over antiplatelet therapy.
          • Non-Vitamin K Antagonist Oral Anticoagulants (NOACs/DOACs): Dabigatran, Rivaroxaban, Apixaban, Edoxaban are generally preferred over warfarin due to comparable efficacy and lower risk of intracranial hemorrhage.
          • Warfarin: Target INR 2.0-3.0.
        • Timing of initiation: Typically delayed for 4-14 days after acute stroke depending on infarct size and hemorrhagic risk (e.g., small infarcts may start sooner, larger infarcts later).
    • Statins:
      • High-intensity statin therapy (e.g., Atorvastatin 80 mg, Rosuvastatin 20-40 mg daily) is recommended for all patients with ischemic stroke of atherosclerotic origin, regardless of baseline LDL-C, to achieve a ≥50% reduction in LDL-C or an LDL-C level <70 mg/dL (1.8 mmol/L).
    • Antihypertensives:
      • Target BP <130/80 mmHg for secondary prevention in patients with hypertension. ACE inhibitors, ARBs, thiazide diuretics, or calcium channel blockers are commonly used.
    • Antidiabetic Medications: Optimize glycemic control (HbA1c target usually <7%).
  • Non-pharmacological:
    • Lifestyle Modification:
      • Diet: Mediterranean diet, DASH diet (Dietary Approaches to Stop Hypertension).
      • Exercise: Regular physical activity (e.g., 30 minutes of moderate-intensity activity most days of the week).
      • Smoking Cessation: Crucial; nicotine replacement therapy, pharmacotherapy (varenicline, bupropion).
      • Alcohol Moderation: Limit to ≤2 drinks/day for men, ≤1 drink/day for women.
      • Weight Management: Maintain healthy BMI (18.5-24.9 kg/m²).
    • Rehabilitation:
      • Physical Therapy (PT): Improve motor function, strength, balance, and mobility.
      • Occupational Therapy (OT): Restore activities of daily living (ADLs) and instrumental ADLs (IADLs).
      • Speech-Language Pathology (SLP): Address dysphagia, aphasia, dysarthria.
      • Cognitive Rehabilitation: For memory, attention, executive function deficits.
      • Psychological Support: Address depression, anxiety, post-stroke fatigue.
  • Monitoring:
    • Regular follow-up appointments with primary care physician and neurologist.
    • Frequent BP monitoring.
    • Periodic lipid panel, HbA1c.
    • Medication adherence review.
    • Screening for post-stroke depression and cognitive impairment.
    • Functional assessments (e.g., modified Rankin Scale, Barthel Index).

Treatment Algorithms

The acute management of ischemic stroke follows a time-sensitive algorithm: - First-Line (within established time windows and criteria): 1. Immediate Brain Imaging (NCCT): To rule out hemorrhage. 2. IV Alteplase: For eligible patients within 4.5 hours of LKN. 3. Endovascular Thrombectomy: For eligible patients with LVO within 6-24 hours of LKN (depending on imaging findings and criteria). Concurrent with or immediately following IV alteplase if also eligible. - Second-Line (for patients not eligible for reperfusion therapies or as adjunctive): 1. Antiplatelet Therapy: Aspirin 325 mg within 24-48 hours (if no alteplase). 2. Aggressive Risk Factor Modification: Early initiation of high-intensity statin, strict BP control, glycemic management. 3. Carotid Revascularization: For symptomatic severe carotid stenosis (≥70% or 50-69% with specific criteria) via carotid endarterectomy (CEA) or carotid artery stenting (CAS), generally delayed until after acute stroke phase (e.g., 2-14 days). - Refractory Cases / Specific Etiologies: * Patent Foramen Ovale (PFO) Closure: Considered for select younger patients (age 18-60) with cryptogenic stroke and a large PFO with right-to-left shunt, especially if recurrent stroke despite antiplatelet therapy. Requires careful patient selection and shared decision-making. (Based on CLOSE, REDUCE, Gore REDUCE trials). * Intracranial Atherosclerosis: Aggressive medical management (antiplatelets, high-intensity statin, BP control) is generally preferred over stenting due to higher periprocedural stroke rates with stenting. * Malignant MCA Infarcts: Hemicraniectomy for large MCA infarcts with cerebral edema causing mass effect, to reduce mortality and improve functional outcome, especially in patients <60 years old.

Complications

  • Common:
    • Aspiration Pneumonia: Due to dysphagia; common and preventable with dysphagia screening.
    • Urinary Tract Infections (UTIs): Especially with indwelling catheters.
    • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Due to immobility; prevented with prophylactic anticoagulation (LMWH, unfractionated heparin) or mechanical devices.
    • Seizures: Occur in 5-10% of stroke patients, more common with cortical infarcts.
    • Depression (Post-stroke Depression): Very common (up to 30-50%), requires screening and treatment.
    • Post-stroke Fatigue: Common and debilitating.
    • Sleep Disturbances.
  • Serious:
    • Hemorrhagic Transformation: Ischemic tissue can bleed, especially after reperfusion therapies or in large infarcts. Symptomatic hemorrhagic transformation occurs in ~6% of alteplase-treated patients.
    • Cerebral Edema and Brain Herniation: Large infarcts can cause significant swelling, leading to increased ICP and herniation, which can be fatal. Malignant MCA edema is a specific example.
    • Recurrent Stroke: Highest risk in the first few days/weeks after the initial event.
    • Acute Hydrocephalus: Can occur rarely, especially with posterior circulation strokes affecting CSF flow.
  • Long-term:
    • Motor Deficits: Spasticity, weakness, impaired coordination leading to long-term disability.
    • Sensory Deficits: Numbness, pain, altered sensation.
    • Aphasia: Speech and language impairments (expressive, receptive).
    • Dysarthria: Slurred speech.
    • Dysphagia: Persistent swallowing difficulties.
    • Cognitive Impairment / Vascular Dementia: Problems with memory, attention, executive function.
    • Neglect: Inattention to one side of space (often left-sided with right hemisphere stroke).
    • Central Post-Stroke Pain: Chronic neuropathic pain.
    • Gait and Balance Impairment: Increased fall risk.
    • Sexual Dysfunction.
    • Social Isolation.

Prognosis

Prognosis varies widely depending on numerous factors. - Factors: * Stroke Severity (NIHSS score): Strongest predictor of outcome. Higher NIHSS at presentation predicts poorer outcome. * Age: Younger patients generally have better recovery potential. * Location and Size of Infarct: Brainstem strokes often have high mortality, large cortical strokes can cause severe deficits. * Time to Reperfusion: Earlier reperfusion is associated with better outcomes. * Etiology: Cardioembolic strokes tend to be more severe. * Comorbidities: Presence of significant comorbidities (e.g., heart failure, severe kidney disease) worsens prognosis. * Early Complications: Hemorrhagic transformation, severe edema, infections negatively impact outcome. * Access to and adherence to Rehabilitation: Crucial for functional recovery. - Survival: * 30-day Mortality: Approximately 10-20% for acute ischemic stroke. * 1-year Mortality: Up to 25-30%. * Mortality rates are significantly higher for severe strokes (e.g., NIHSS >20). - Quality of Life: * Functional Outcome: Assessed using scales like the modified Rankin Scale (mRS), where 0 = no symptoms, 6 = death. * mRS 0-1 (Excellent outcome): Occurs in a minority of patients, more likely with mild strokes or early successful reperfusion. * mRS 0-2 (Good functional outcome/functional independence): The target outcome for acute stroke interventions (e.g., observed in 30-50% of thrombectomy patients). * Approximately 50% of stroke survivors experience some degree of long-term disability. * Significant impact on independence, employment, social participation, and mental health due to physical, cognitive, and emotional sequelae.

Prevention

Primary Prevention (Preventing the first stroke)

Focuses on managing modifiable risk factors in the general population. - Blood Pressure Control: Aggressive management of hypertension to a target generally <130/80 mmHg for most adults. - Diabetes Management: Optimize glycemic control (HbA1c usually <7%), but avoid severe hypoglycemia. - Dyslipidemia Management: Lifestyle modifications and statin therapy, especially for those at high risk (e.g., target LDL-C <100 mg/dL or <70 mg/dL for very high risk). - Smoking Cessation: Crucial. Counseling, pharmacotherapy (varenicline, bupropion), and nicotine replacement therapy. - Healthy Diet: Emphasize fruits, vegetables, whole grains, lean protein, and limit saturated/trans fats, sodium, and added sugars (e.g., Mediterranean or DASH diet). - Regular Physical Activity: At least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity aerobic activity per week, plus muscle-strengthening activities. - Weight Management: Maintain a healthy BMI (18.5-24.9 kg/m²). - Moderate Alcohol Consumption: Limit to ≤2 drinks/day for men and ≤1 drink/day for women. - Atrial Fibrillation Screening: Opportunistic screening (pulse check) in adults >65 years. - Antiplatelet Therapy (Aspirin): Not routinely recommended for primary prevention in healthy individuals due to bleeding risk. May be considered for select patients with high cardiovascular risk and low bleeding risk.

Secondary Prevention (Preventing recurrent stroke)

Crucial for patients who have already experienced a stroke or TIA. - Pharmacological: * Antiplatelet Agents: Aspirin, clopidogrel, or aspirin + extended-release dipyridamole. DAPT (aspirin + clopidogrel) for 21-90 days for minor stroke/high-risk TIA. * Oral Anticoagulation: For cardioembolic stroke (e.g., atrial fibrillation) with DOACs or warfarin. * High-Intensity Statins: Regardless of baseline lipid levels, for atherosclerotic stroke. * Antihypertensives: To achieve target BP <130/80 mmHg. - Risk Factor Management: Strict control of all modifiable risk factors as in primary prevention. - Carotid Revascularization: * Carotid Endarterectomy (CEA): For symptomatic carotid stenosis ≥70%, significantly reduces recurrent stroke risk. Also considered for 50-69% symptomatic stenosis. * Carotid Artery Stenting (CAS): Alternative to CEA for symptomatic stenosis in patients who are high surgical risk, or anatomically unsuitable for CEA. - PFO Closure: Considered for selected patients aged 18-60 with cryptogenic stroke and a large PFO with significant right-to-left shunt, especially after full workup for other causes. - Lifestyle Modifications: Continuous emphasis on healthy diet, regular exercise, smoking cessation, and weight management.

Tertiary Prevention (Minimizing disability and complications post-stroke)

Focuses on rehabilitation and long-term care. - Comprehensive Rehabilitation Programs: PT, OT, SLP, cognitive rehabilitation, neuropsychology. - Management of Complications: Prevention and treatment of aspiration pneumonia, DVT/PE, UTIs, spasticity, pain, depression, and cognitive impairment. - Psychosocial Support: For patients and caregivers to cope with physical and emotional challenges. - Long-term Monitoring: Regular follow-up with healthcare providers to optimize medication adherence and manage chronic conditions.

Special Populations

  • Pediatric Stroke:
    • Epidemiology: Rare (2-13 cases per 100,000 children per year).
    • Etiologies: Differ significantly from adults. Common causes include congenital heart disease, sickle cell disease, vasculopathies (e.g., focal cerebral arteriopathy, moyamoya disease), prothrombotic conditions, head/neck trauma, and infections.
    • Clinical Presentation: Can be subtle and non-specific. Often presents with seizures (most common), headache, altered consciousness, or acute hemiparesis.
    • Management: Acute reperfusion therapies (alteplase, thrombectomy) are generally not recommended outside of clinical trials due to lack of evidence, but may be considered in highly selected cases. Focus on identifying and treating underlying etiology and supportive care.
  • Geriatric Stroke:
    • Higher Incidence and Severity: Older age is the strongest non-modifiable risk factor. Older patients tend to have more severe strokes and poorer outcomes.
    • Increased Comorbidities: More likely to have multiple chronic conditions (e.g., atrial fibrillation, heart failure, renal impairment, polypharmacy), which complicate management.
    • Challenges in Management: Higher risk of complications (e.g., hemorrhagic transformation with thrombolysis, infections). May have atypical presentations (e.g., delirium masking focal deficits).
    • Rehabilitation: While recovery potential may be slower, rehabilitation is still beneficial and crucial for maintaining function.
  • Pregnancy and Puerperium:
    • Increased Risk: Stroke risk is elevated during pregnancy and especially in the puerperium (first 6 weeks postpartum). Causes include preeclampsia/eclampsia, reversible cerebral vasoconstriction syndrome, cerebral venous thrombosis, peripartum cardiomyopathy, and hypercoagulable state of pregnancy.
    • Diagnosis: Imaging (MRI without gadolinium preferred over CT to minimize fetal radiation).
    • Management:
      • Acute: Thrombolysis (alteplase) can be considered if benefits outweigh risks, but data are limited. Thrombectomy is an option if indicated. Blood pressure management is critical, with caution regarding certain antihypertensives (e.g., ACE inhibitors contraindicated).
      • Anticoagulation: Low molecular weight heparin (LMWH) or unfractionated heparin are preferred for antithrombotic therapy over warfarin in most of pregnancy. Aspirin is safe in pregnancy.
    • Preeclampsia/Eclampsia: Aggressive BP control and seizure prevention/management.
  • Comorbidities:
    • Diabetes: Requires strict glucose control to prevent hyperglycemia-induced neuronal damage and to reduce secondary stroke risk.
    • Renal Disease: Affects drug metabolism and clearance (e.g., dosing of DOACs). Increases risk of contrast-induced nephropathy during imaging.
    • Heart Failure: Increases risk of cardioembolic stroke. Requires careful fluid management during acute phase.
    • Cancer: Can be a hypercoagulable state (Trousseau's syndrome), increasing risk of stroke. Management requires collaboration with oncology.

Clinical Pearls

  • Diagnostic:
    • "Time is Brain": The single most important concept in acute stroke management. Every minute counts. Rapid assessment and imaging are paramount.
    • Rule out stroke mimics: Hypoglycemia, seizures (Todd's paralysis), migraine with aura, Bell's palsy, conversion disorder can mimic stroke. Always check blood glucose.
    • "Last Known Normal" (LKN): Accurately determining LKN is critical for reperfusion therapy eligibility. For wake-up strokes, LKN is the time the patient was last observed to be without symptoms.
    • NIHSS Score: A robust and reliable tool for quantifying stroke severity and guiding treatment decisions.
    • Imaging is key: NCCT to rule out hemorrhage. CTA to identify LVO. Perfusion imaging for extended window thrombectomy.
  • Treatment:
    • Strict BP Control for Alteplase: Do not initiate alteplase if SBP >185 or DBP >110 mmHg. Maintain SBP <180 and DBP <105 mmHg for 24 hours post-alteplase.
    • Dysphagia Screening: Perform a formal swallow screen before any oral intake to prevent aspiration.
    • Early Mobilization: Unless contraindicated, early mobilization and rehabilitation should begin as soon as the patient is medically stable.
    • Temperature Control: Aggressively manage fever, as it worsens neurological outcome.
    • Glucose Management: Avoid both hyperglycemia and hypoglycemia.
    • Secondary Prevention is Lifelong: Emphasize importance of medication adherence and lifestyle changes for all patients post-stroke.
  • Pitfalls:
    • Delaying imaging: Not performing immediate NCCT/CTA can miss the narrow window for reperfusion therapies.
    • Misinterpreting CT scan: Missing subtle early ischemic changes or small hemorrhages.
    • Incorrect LKN: Leading to inappropriate administration or withholding of alteplase.
    • Inadequate BP management: Either uncontrolled hypertension (risk of hemorrhagic conversion) or overly aggressive BP lowering (risk of worsening ischemia).
    • Ignoring dysphagia: Leading to aspiration pneumonia, a common and potentially fatal complication.
    • Failing to screen for and treat post-stroke depression: Which significantly impacts quality of life and rehabilitation outcome.
    • Incomplete etiological workup: Not identifying the cause of stroke can lead to recurrent stroke (e.g., missing atrial fibrillation).

Recent Updates

  • Guidelines:
    • 2019 AHA/ASA Guidelines for the Early Management of Patients with Acute Ischemic Stroke: Reinforced and expanded the role of endovascular thrombectomy, updated BP management recommendations, and emphasized rapid assessment.
    • 2021 AHA/ASA Guidelines for the Secondary Prevention of Stroke: Updated recommendations on antithrombotic therapy (DAPT for minor stroke/TIA), statin therapy, BP targets, and PFO closure.
  • Evidence:
    • Expanded Thrombectomy Window: DAWN and DEFUSE 3 trials (2018) revolutionized LVO treatment, demonstrating efficacy of thrombectomy out to 16-24 hours based on advanced imaging (perfusion-diffusion mismatch or clinical-core mismatch).
    • Dual Antiplatelet Therapy (DAPT): POINT (2018) and CHANCE (2013) trials demonstrated benefit of short-term (21-90 days) DAPT with aspirin + clopidogrel for minor ischemic stroke (NIHSS ≤5) or high-risk TIA within 24 hours of onset, reducing recurrent stroke risk but increasing major hemorrhage risk slightly.
    • PFO Closure: Meta-analyses of trials (CLOSE, REDUCE, GORE REDUCE, RESPECT) have shown PFO closure reduces recurrent stroke risk in carefully selected younger patients with cryptogenic stroke, often with a large shunt.
  • Controversies:
    • Optimal Blood Pressure Target in Acute Stroke without Reperfusion: Debate continues on the ideal BP target for patients not receiving thrombolysis, balancing perfusion to ischemic penumbra versus prevention of hemorrhagic transformation.
    • Long-term DAPT after Minor Stroke: The optimal duration and role of DAPT beyond 90 days for certain subgroups remains debated.
    • Role of PFO Closure: While evidence supports PFO closure in selected patients, the definition of "selected" and the long-term benefits versus risks continue to be refined.

Key References

  • Guidelines:
    • Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Mar;50(3):e344-e418.
    • Kleindorfer DO, Towfighi AS, Kissela SS, et al. 2021 Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467.
  • Landmark Studies:
    • NINDS rt-PA Stroke Study Group (1995): Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587. (Established alteplase efficacy within 3 hours).
    • ECASS III (2008): Intravenous rt-PA for acute ischemic stroke in the 3- to 4.5-hour window. N Engl J Med. 2008;359(13):1317-1329. (Expanded alteplase window).
    • MR CLEAN (2015): A randomized trial of intra-arterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20. (First positive thrombectomy trial).
    • DAWN Trial (2017): Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2017;377(23):2252-2261.
    • DEFUSE 3 (2018): Endovascular Thrombectomy for Ischemic Stroke with Perfusion-Imaging Selection. N Engl J Med. 2018;378(1):11-21. (Expanded thrombectomy window to 16-24 hours).
    • POINT Trial (2018): Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018;379(3):215-225. (DAPT for minor stroke/TIA).
    • CHANCE Trial (2013): Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(11):1084-1084. (DAPT for minor stroke/TIA).
  • Reviews:
    • UpToDate: Acute ischemic stroke: Initial management and prognosis. (Accessed regularly for current recommendations).
    • Caplan LR. Stroke: A Clinical Approach. 5th ed. Elsevier; 2016.
    • Adams HP Jr, Adams RJ, del Zoppo G, et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005 May;36(5):916-23.

Dr. Vivek's AI | For Educational Purposes Only